Significant results for polycythemia vera patients on Jakavi®

Novartis has announced results from the first-ever pivotal Phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera (PV).

Source: Pharmacy Europe - June 16, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Oncology Latest News Source Type: news